Palliative care in malignant haematology: An overview

HAEMA

Volumn 8, Issue 2, 2005, Pages 215-233

  Niscola, Pasquale ^a,k   Scaramucci, Laura ^b   Giovannini, Marco ^c   Anghel, Gabriel ^d   Romani, Claudio ^e   Palombi, Francesca ^f   Trapè, Giulio ^g   Morabito, Fortunato ^h   Conte, Esmeralda ⁱ   Cedrone, Michele ^j   Arcuri, Edoardo ^f  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Montefiascone Hospital   (Italy)

^c ASL Frosinone   (Italy)

^d Azienda San Camillo Forlanini   (Italy)

^e Ospedale Oncologico A Businco   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j Hematology Service   (Italy)

^k S EUGENIO HOSPITAL   (Italy)

more..

Author keywords

Hematological malignancies; Hematology; Palliative care; Symptom relief; Terminal illness

Indexed keywords

AMIKACIN; ANALGESIC AGENT; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CEFTRIAXONE; CIPROFLOXACIN; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; IRON; KETAMINE; LEXIDRONAM SAMARIUM SM 153; LIDOCAINE; METHOTREXATE; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID; PHOSPHONIC ACID DERIVATIVE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TACROLIMUS; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZOLEDRONIC ACID;

ANEMIA; BLEEDING; BLOOD CLOTTING DISORDER; BONE DISEASE; BONE PAIN; DIET; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; KIDNEY DISEASE; LAMINECTOMY; MEDICAL SPECIALIST; MENINGITIS; MOUTH HYGIENE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUROPATHIC PAIN; NEUTROPENIA; NOCICEPTION; PALLIATIVE THERAPY; PATIENT CARE; PRACTICE GUIDELINE; QUALITY OF LIFE; RADIOISOTOPE THERAPY; REHYDRATION; REVIEW; SPINAL CORD COMPRESSION; STEM CELL TRANSPLANTATION; SUSTAINED RELEASE PREPARATION; TERMINAL DISEASE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 21744461220     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (230)

1. Stalfelt AM, Brodin H, Pettersson S, Eklof A. The final phase in acute myeloid leukaemia (AML). A study on bleeding, infection and pain. Leuk Res 2003; 27: 481-488.
2. Symptom relief in terminal illness. WHO, Geneva, Swiss, 1998.
3. Abrahm JL. Update in palliative medicine and end-of-life care. Annu Rev Med 2003; 54: 53-72.
4. Himelstein BP, Hilden JM, Boldt AM, Weissman D. Pediatric palliative care. N Engl J Med 2004; 350: 1752-1762.
5. Niscola P, Cartoni C, Moleti ML et al. Home Care in Hematology. Acta Med Rom 2000; 38: 338-344.
6. Cartoni C, Cedrone M, De Gregoris C et al. Early discharge and home care management of therapy-induced neutropenic AML patients. Br J Haematol 1998; 102(suppl. 1): 224.
7. McGrath P, Joske D. Palliative care and haematological malignancy: a case study. Aust Health Rev 2002; 25: 60-66.
8. Boyce A, McHugh M, Lyon P. Proactive palliative care choices for haematology day unit patients. Int J Palliat Nurs 2003; 9: 544-550.
9. Meyers FJ, Linder J. Simultaneous Care: Disease Treatment and Palliative Care Throughout Illness. J Clin Oncol 2003; 21: 1412-1415.
10. Schevchenko YK, Novik AA, Ionova TI. Quality of life is a key point of decision making paradigm in hematooncology. Hematol J 2004; 5(suppl. 2): S261
11. Meier DE, Thar W, Jordan A, Goldhirsch SL, Siu A, Morrison RS. Integrating case management and palliative care. J Palliat Med 2004; 7: 119-134.
12. Surbone A. There is no dividing line. Crit Rev Oncol Hematol 2003; 46: 1-3.
13. Bulsara C, Ward A, Joske D. Haematological cancer patients: achieving a sense of empowerment by use of strategies to control illness. J Clin Nurs 2004; 13: 251-258.
14. Mander T. Haematology and palliative care: an account of shared care for a patient undergoing bone marrow transplantation for chronic myeloid leukaemia. Int J Nurs Pract 1997; 3: 62-66.
15. Casini C, Carrai V, Innocenti F et al. Hematological Home Care (HCC): ten years activity. Hematol J 2002; 3(suppl. 1): 84.
16. Cartoni C, Brunetti GA, D'Elia GM, et al. Home care for patients with hematologic malignancies. Hematol J 2002; 3(suppl. 1): 84.
17. Scaramucci L, Niscola P, Cosenza M et al. Home care in hematology: the experience of an Italian single institution. Int J Hematol 2002; (suppl.): 223.
18. Montanaro M, Niscola P, Radini B, Scaramucci L, Pierelli L. The "Hematological Hospital in the Home" project of the Azienda ASL Viterbo (Italy). Haematologica 2003; 88(suppl. 15): 114-115.
19. Miano M, Manfredini L, Garaventa A et al. Feasibility of a home care program in a pediatric hematology and oncology department. Results of the first year of activity at a single Institution. Haematologica 2002; 87: 637-642.
20. ESMO. ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 2001; 12: 1059-1060.
21. Abdulrahman IS. A prospective study of renal failure in multiple myeloma: a promising role for plasmapheresis. Haema 2003; 6: 358-365.
22. Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 2003; 29: 467-471.
23. Funke I, Wiesneth M, Platow S, Kubanek B. Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients. Ann Hematol 2000; 79: 132-137.
24. McLeod BC. Introduction to the third special issue: clinical applications of therapeutic apheresis. J Clin Apheresis 2000; 15: 1-5.
25. Zarkovic M, Kwaan HC. Correction of hyperviscosity by apheresis. Semin Thromb Hemost 2003; 29: 535-542.
26. Dunn A, Carter J, Carter H. Anemia at the end of life: prevalence, significance, and causes in patients receiving palliative care. J Pain Symptom Manage 2003; 26: 1132-1139.
27. Novik AA, Ionova TI, Wang XC et al. Quality of life impairment and prevailing symptoms in patients with advanced hematological malignancies. Hematology J 2004; 5(suppl. 2): S278.
28. Newton S. Haematology and palliative care: blood, sweat and tears. Int Med J 2003; 33: 549-551.
29. Drews RE. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med 2003; 24: 607-622.
30. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 2003; 98: 1786-1801.
31. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004; 32: 40-50.
32. Mock V. Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monogr 2004; 32: 112-118.
33. Gleeson C, Spencer D. Blood transfusion and its benefits in palliative care. Palliat Med 1995; 9: 307-313.
34. Monti M, Castellani L, Berlusconi A, Cunietti E. Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manage 1996; 12: 18-22.
35. Kasper C. Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies. Ann Hematol 2001; 80: 319-329.
36. Ludwig H, Rai K, Blade J et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia:epoetin treatment recommendations. Hematol J 2002; 3: 121-130.
37. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998; 103: 1070-1074.
38. Stein RS. The role of erythropoietin in the anemia of myelodysplastic syndrome. Clin Lymph 2003; 4(suppl. 1): S36-S40.
39. Lumadue JA, Ness PM. Current approaches to red blood cell transfusion. Semin Hematol 1996; 33: 277-289.
40. Dammacco F, Marschner N, Gamacorta M. Epoetin alfa improves hemoglobin levels and quality of life parameters in anemic patients with hematologic malignancies receiving chemotherapy: interim results from the EPOLYM trial. Hematol J 2004; 5(suppl. 2): S177.
41. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
42. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888-895.
43. Rizzo JD, Lichtin AE, Woolf SH et al. American Society of Clinical Oncology. American Society of Hematology. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083-4107.
44. Petti MC, Niscola P, Cortellezzi A et al. Effective of a new dosing regimen of epoetin on anemia and quality of life in low risk myelodysplastic syndrome patients. Haematologica 2003; 88(suppl. 15): 117-118.
45. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-2882.
46. Niscola P, Scaramucci L, Menichelli L et al. High-doses epoetin alpha in patients with multiple myeloma-related anaemia: early response and effective maintenance treatment with a longer dosing interval. Haema 2003; 6: 259-264.
47. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multieenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307.
48. Bosanquet N, Tolley K. Treatment of anaemia in cancer patients: implications for supportive care in the National Health Service Cancer Plan. Curr Med Res Opin 2003; 19: 643-650.
49. Tanneberger S, Melilli G, Strocchi E, Frenquelli C, Pannuti QF. Use of red blood cell transfusion in palliative care services: is it still up to date or is cancer-related anaemia controlled better with erythropoietic agents? Ann Oncol 2004; 15: 839-840.
50. Avvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol 2003; 48(suppl.): S13-S16.
51. Nevo S, Vogelsang GB. Acute bleeding complications in patients after bone marrow transplantation. Curr Opin Hematol 2001; 8: 319-325.
52. Nevo S, Swan V, Enger C et al. Acute bleeding after bone marrow transplantation (BMT)- incidence and effect on survival. A quantitative analysis in 1,402 patients. Blood 1998; 91: 1469-1477.
53. Cartoni C, Cedrone M, De Gregoris C et al. Domiciliary management of hemorrhage for patients with advanced-phase hematologic neoplasm. Br J Haematol 1998; 102(suppl. 1): 337.
54. Avvisati G, Wouter Ten Cate J, Buller HR et al. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989; 2: 122-124.
55. Dean A, Tuffin P. Fibrinolytic inhibitors of cancer-associated bleeding problems. J Pain Symptom Manage 1997; 13: 20-24.
56. Mannucci PM. Hemostatic Drugs. N Engl J Med 1998; 339: 245-253.
57. Hollander D, Tarnaski A. The protective and therapeutic mechanism of sucralfate. Scand J Gastroenterol 1990; 25(suppl. 173): 1-5.
58. Rebulla P, Finazzi G, Marangoni F et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo ltaliano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997; 337: 1870-1875.
59. McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol 2000; 37(suppl. 4): 3-10.
60. Schiffer CA, Anderson KC, Bennett CL et al. American Society of Clinical Oncology. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-1538.
61. De Fahritiis P, Dentamaro T, Picardi A, Cudillo L, Masi M, Amadori S Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies. Haematologica 2004; 89: 243-245.
62. Gerotziafas GT, Zervas K, Arzoglou P et al. On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation. Br J Haematol 2002; 117: 705-708.
63. Girmenia C, Moleti ML, Cartoni C et al.: management of infective complications in patients with advanced haematologic malignancies in home care. Leukaemia 1997; 11: 1807-1812.
64. Vitetta L, Kenner D, Sali A. Bacterial infections in terminally ill hospice patients. J Pain Symptom Manage 2000; 20: 326-334.
65. Herrmann RP, Trent M, Cooney J, Cannell PK. Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 1999; 24: 1213-1217.
66. Centers for Disease Control and Prevention. Infectious Disease Society of America. American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49: 1-125.
67. Hughes WT, Armstrong D, Bodey GP et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
68. Del Favero A, Bucaneve G, Furno F. Choice of empirical therapy and prophylaxis. Hematol J 2004; 5(suppl. 3): S53-S58.
69. Koh A, Pizzo PA. Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia. Cancer Invest 2002; 20: 420-433.
70. Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305-311.
71. Martino P, Girmenia C, Raccah R et al. Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 1992; 49: 49-52.
72. Minotti V, Gentile G, Bucaneve G et al. A Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer 1999; 7: 134-139.
73. Pereira J, Watanabe S, Wolch G. A retrospective review of the frequency of infections and patterns of antibiotic utilization on a palliative care unit. J Pain Symptom Manage 1998; 16: 374-381.
74. Nagy-Agren S, Haley H. Management of infections in palliative care patients with advanced cancer. J Pain Symptom Manage 2002; 24: 64-70.
75. Schubert MM. Oral Mucositis. Oncology (Special Edition) 2004; 7: 51-54.
76. Sonis ST, Oster G, Fuchs H et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19: 2201-2205.
77. Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology 2003; 17: 1767-1779.
78. Sonis ST, Elting LS, Keefe D et al. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100(suppl.): 1995-2025.
79. Brown CG, Wingard J. Clinical consequences of oral mucositis. Semin Oncol Nurs 2004; 20: 16-21.
80. Sweeney MP, Bagg J. The mouth and palliative care. Am J Hosp Palliat Care 2000; 17: 118-124.
81. Dahlin C. Oral complications at the end of life. Am J Nurs 2004; 104: 40-47.
82. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4: 277-284.
83. Dominguez Reyes A, Aznar Martin T, Barberia Leache E, Cabrera Suarez E. Oral manifestations of graft versus host disease. Case report. Med Oral 2003; 8: 361-365.
84. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Head Neck 2004; 26: 77-84.
85. Bolwell BJ, Kalaycio M, Sobecks R et al. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 2002; 30: 587-591.
86. Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004; 22: 1268-1275.
87. Ulrich CM. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98: 231-234.
88. Eilers J, Epstein JB. Assessment and measurement of oral mucositis. Semin Oncol Nurs 2004; 20: 22-29.
89. Cella D, Pulliam J, Fuchs H et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 2003; 98: 406-412.
90. Daniel BT, Damato KL, Johnson J. Educational issues in oral care. Semin Oncol Nurs 2004; 20: 48-52.
91. Sironi M, Milanese C, Vecchi A et al. Benzydamine inhibits the release of tumor necrosis factor-alpha and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells. Int J Clin Lab Res 1997; 27: 118-122.
92. McGuire DB, Rubenstein EB, Peterson DE. Evidence-based guidelines for managing mucositis. Semin Oncol Nurs 2004; 20: 59-66.
93. Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis 2003; 3: 405-412.
94. Rubenstein EB, Peterson DE, Schubert M et al. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100(suppl. 9): 2026-2046.
95. Meloni G, Capria S, Proia A et al. Ice pops to prevent melphalan-induced stomatitis. Lancet 1996; 347: 1691-1692.
96. Capelli D, Santini G, De Souza C et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 2000; 110: 300-307.
97. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002; 13: 181-209.
98. Cockerham MB, Weinberger BB, Lerchie SB. Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother 2000; 34: 300-303.
99. Piccirillo N, De Matteis S, Sora F et al. Glutamine parenteral supplementation in stem cell transplant. Bone Marrow Transplant 2004; 33: 455.
100. Yuen KY, Woo PC, Tai JW et al. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica 2001; 86: 554-555.
101. Van der Lelie H, Thomas BL, van Oers RH et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Ann Hematol 2001; 80: 150-154.
102. Braun S, Hanselmann C, Gassmann MG et al. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 2002; 22: 5492-5505.
103. Spielberger R, Stiff P, Emmanouilides C et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning-results of a phase 2 trial. Proc Am Soc Clin Oncol 2001; 20: 7a.
104. Meropol NJ, Somer RA, Gutheil J et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21: 1452-1458.
105. Stadler M, Starke O, Reuter CWM, Eckardt B, Hertenstein B. Higly effective topical tacrolimus treatment in several oral chronic Graft-Versus-Host Disease following allogenic hematopoietic stem cell transplantation. Hematol J 2004; 5(suppl. 2): S158.
106. Castilla C, Perez Simon JA, Sanchez-Guijo F et al. Topic therapy on gut acute Graft-Versus-Host Disease (GVHD). Hematol J 2004; 5(suppl. 2): S160.
107. Epstein JB, Schubert MM. Managing pain in mucositis. Semin Oncol Nurs 2004; 20: 30-37.
108. Cerchietti LC, Navigante AH, Korte MW et al. Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain 2003; 105: 265-273.
109. Slatkin NE, Rhiner M. Topical ketamine in the treatment of mucositis pain. Pain Med 2003; 4: 298-303.
110. Hill HF, Chapman CR, Kornell JA et al. Self-administration of morphine in bone marrow transplant patients reduces drug requirement. Pain 1990; 40: 121-129.
111. Chapman CR, Donaldson GW, Jacobson RC, Hautman B. Differences among patients in opioid self-administration during bone marrow transplantation. Pain 1997; 71: 213-223.
112. Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 2002; 95: 203-208.
113. Burza M, Ginobbi P, Fusco G et al. Transdermal route as an alternative to oral administration of opioids in cancer pain. Clin Ter 1998; 149: 277-280.
114. Nosari A, Anghilieri M, Cozzi P et al. Transdremal Fentanyl is useful in Chemotherapy-Associated Mucositis. Blood 2002; 100:(suppl., part 1): 387b.
115. Barille-Nion S, Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma 2003; 44: 1463-1467.
116. Durr HR, Muller PE, Hiller E et al. Malignant lymphoma of bone. Arch Orthop Trauma Surg 2002; 122: 10-16.
117. Moazzam N, Malik AA, Potti A. B-cell lymphoma mimicking multiple myeloma. Leuk Lymphoma 2002; 43: 1869-1873.
118. Lal A, Tallman MS, Soble MB et al. Hairy cell leukemia presenting as localized skeletal involvement. Leuk Lymphoma 2002; 43: 2207-2211.
119. Matsushima T, Yamamoto M, Sakai K. Multiple osteolysis of peripheral extremities in a patient with adult T cell leukemia/lymphoma. Intern Med 1999; 38: 820-823.
120. Muta T, Osaki K, Yamano Y. Translocation t (9; 22) (p23; q11) in atypical chronic myeloid leukemia (aCML) presenting osteolytic lesions. Int J Hematol 2002; 76: 344-348.
121. Lima CS, Pinto Neto JV, da Cunha ML et al. Osteolytic lesions as a presenting sign of acute myeloid leukemia. Haematologia 2000; 30: 325-331.
122. Muller HL, Horwitz AE, Kuhl J. Acute lymphoblastic leukemia with severe skeletal involvement: a subset of childhood leukemia with a good prognosis. Pediatr Hematol Oncol 1998; 15: 121-33.
123. Athale UH, Kaste SC, Razzouk BI et al. Skeletal manifestations of pediatric acute megakaryoblastic leukemia. J Pediatr Hematol Oncol 2002; 24: 561-565.
124. Abbas AA, Baker DL, Felimban KS, Husain AH. Musculoskeletal and radiological manifestations of childhood acute leukaemia: a clinical review. Haema 2004; 7: 448-455.
125. Aric M, Boccalatte MFP, Silvestri D et al. Osteonecrosis: an emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica 2003; 88: 747-753.
126. Sjak-Shie NN, Vescio RA, Berenson JR. Recent advances in multiple myeloma. Curr Opin Hematol 2000; 7: 241-246.
127. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998; 16: 1218-1225.
128. Berenson JR, Hillner BE, Kyle RA et al. American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20: 3719-3736.
129. Durie BG, Kyle RA, Belch A et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2004; 5: 285.
130. Pistevou-Gombaki K, Eleftheriadis N, Sofroniadis I et al. Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate. J Exp Clin Cancer Res 2002; 21: 429-432.
131. Chern B, Joseph D, Joshua D et al. Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer 2004; 12: 463-466.
132. Berenson J, Hirschberg R. Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid. Oncologist 2004; 9: 319-329.
133. Smith AG, Soutar RL, Schey S et al. Home care versus hospital care in patients with multiple myeloma treated with pamidronate. Int J Palliat Nurs 2004; 10: 144-149.
134. Iuliano F, Abruzzese E, Molica S et al. Samarium (Sm) 153 Ethylene Diamine Tetramethylene Phosphonate (153Sm-EDTMP) Targeted radiotherapy and Zolendronic acid is an effective option for elderly with symptomatic refractory Multiple Myeloma. Blood 2003; 102(suppl. part I): 446a.
135. Lee CK, Aeppli DM, Unger J, Boudreau RJ, Levitt SH. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience. Am J Clin Oncol 1996; 19: 102-107.
136. Kucuk NO, Ibis E, Aras G et al. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases. Ann Nucl Med 2000; 14: 239-245.
137. Saarto T, Janes R, Tenhunen M, Kouri M. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain 2002; 6: 323-330.
138. Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiother Oncol 1999; 52: 111-121.
139. van den Hout WB, van der Linden YM, Steenland E et al. Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003; 95: 222-229.
140. Mose S, Pfitzner D, Rahn A, Nierhoff C, Schiemann M, Bottcher HD. Role of radiotherapy in the treatment of multiple myeloma. Strahlenther Onkol 2000; 176: 506-512.
141. Leigh BR, Kurtts TA, Mack CF, Matzner MB, Shimm DS. Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys 1993; 25: 801-804.
142. Bosch A, Prias Z. Radiotherapy in the treatment of multiple myeloma. Int J Radiat Oncol Biol Phys 1988; 15: 1363-1399.
143. Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology 2000; 14: 101-108.
144. Koswig S, Budach V. Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther Onkol 1999; 175: 500-508.
145. Durr HR, Wegener B, Krodel A et al. Multiple myeloma: surgery of the spine: retrospective analysis of 27 patients. Spine 2002; 27: 320-324.
146. Dudeney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 2002; 20: 2382-2387.
147. Fourney DR, Schomer DF, Nader R et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 2003; 98(suppl.): 21-30.
148. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80(8 suppl): 1588-1594.
149. Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappa B ligand on adult T-cell leukemia cells. Blood 2002; 99: 634-640.
150. Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002; 29(suppl. 21): 12-18.
151. Wenzel C, Bartsch R, Hussian D et al. Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome. Support Care Cancer 2004; 12: 678-681.
152. Perry CM, Figgitt DP. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 2004; 64: 1197-1211.
153. Demopoulos A, DeAngelis LM. Neurologic complications of leukemia. Curr Opin Neurol 2002; 15: 691-699.
154. Ferrer A, Borsch F, Lopez-Guillermo A et al. Central Nervous System (CNS) involvement in antle cell lymphoma (MCL). Hematol J 2004; 5(suppl. 2): S114.
155. Sheehan T, Cuthbert RJ, Parker AC. Central nervous system involvement in haematological malignancies. Clin Lab Haematol 1989; 11: 331-338.
156. Chamberlain MC. Neoplastic meningitis: a guide to diagnosis and treatment. Curr Opin Neurol 2000; 13: 641-648.
157. Kim L, Glantz MJ. Neoplastic meningitis. Curr Treat Options Oncol 2001; 2: 517-527.
158. Amadori S, Papa G, Avvisati G et al. Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma. J Clin Oncol 1984; 2: 98-101.
159. Berg SL, Chamberlain MC. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 2003; 5: 29-40.
160. Ruggiero A, Conter V, Milani M et al. Intrathecal chemotherapy with antineoplastic agents in children. Paediatr Drugs 2001; 3: 237-246.
161. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003; 97: 3053-3060.
162. Jaeckle KA, Batchelor T, O'Day SJ. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002; 57: 231-239.
163. Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101: 466-468.
164. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89: 753-754.
165. Hanssens PE, Lagerwaard FJ, Levendag PC. Principles of radiotherapy of neoplastic meningosis. J Neurooncol 1998; 38: 145-150.
166. Sanders KE, Ha CS, Cortes-Franco JE, Koller CA, Kantarjian HM, Cox JD. The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer 2004; 100: 2176-2180.
167. Benson WJ, Scarffle JH, Todd ID, Palmer M, Crowther D. Spinal-cord compression in myeloma. BMJ 1979; 1: 1541-1544.
168. Wallington M, Mendis S, Premawardhana U, Sanders P, Shahsavar-Haghighi K. Local control and survival in spinal cord compression from lymphoma and myeloma. Radiother Oncol 1997; 42: 43-47.
169. Bach F, Larsen BH, Rohde K et al. Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir 1990; 107: 37-43.
170. Shah BK, Saifuddin A, Price GJ. Magnetic resonance imaging of spinal plasmacytoma. Clin Radiol 2000; 55: 439-445.
171. Vecht CJ, Haaxma-Reiche H, van Putten WL, de Visser M, Vries EP, Twijnstra A. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology 1989; 39: 1255-1257.
172. Loblaw DA, Lapierre NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol 1998; 16: 1613-1624.
173. Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30: 22-27.
174. Maranzano E, Trippa F, Chirico L, Basagni ML, Rossi R. Management of metastatic spinal cord compression. Tumori 2003; 89: 469-475.
175. Hoskin PJ, Grover A, Bhana R. Metastatic spinal cord compression: radiotherapy outcome and dose fractionation. Radiother Oncol 2003; 68: 175-180.
176. Sundaresan N, Sachdev VP, Holland JF et al. Surgical treatment of spinal cord compression from epidural metastasis. J Clin Oncol 1995; 13: 2330-2335.
177. Niscola P, Arcuri E, Giovannini M et al. Pain syndromes in haematological malignancies: an overview. Hematol J 2004; 5: 293-303.
178. Niscola P, Cartoni C, Arcuri E et al. Epidemiologia e fisiopatogenesi del dolore nelle neoplasie ematologiche in fase avanzata. La Rivista Italiana di Cure Palliative (RICP) 2000; 2: 157-161.
179. Novik A, Manikhas G. Comparison of Symptom Severity and Prevalence between Hematological Malignancies and Solid tumors among Russian Oncology Patients. Blood 2002; 100(suppl., part 1): 387b
180. Caraceni A, Weinstein SM. Classification of cancer pain syndromes. Oncology 2001; 15: 1627-1640, 1642.
181. Mach DB, Rogers SD, Sabino MC et al. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 2002; 113: 155-166.
182. Clohisy DR, Mantyh PW. Bone cancer pain. Cancer 2003; 97(suppl. 3): 866-873.
183. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998; 338: 1601-1607.
184. Gnann JW, Whitley RJ. Herpes Zoster. N Engl J Med 2002; 347: 340-346.
185. Caraceni A, Cherny N, Fainsinger R et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 2002; 23: 239-255.
186. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999; 53: 1695-1700.
187. Rubens RD, Towlson KE, Ramirez AJ et al. Appropriate chemotherapy for palliating advanced cancer. BMJ 1992; 304: 35-40.
188. Giovannini M, Cartoni C, Cedrone M et al. Chemioterapia palliativa in pazienti con neoplasie ematologiche in fase avanzata di malattia: esperienza dell'Unità di Cure domiciliari "Romail" presso l'Istituto d'Ematologia dell' Università "La sapienza" di Roma. (Abstract). Paper presented at the eighth Congress of the Società Italiana di Cure Palliative, Genoa, 1997.
189. Mereadante S, Fulfaro F, Casuccio A. The use of corticosteroids in home palliative care. Support Care Cancer 2001; 9: 386-389.
190. Weinmann M, Becker G, Einsele H, Bamberg M. Clinical indications and biological mechanisms of splenic irradiation in chronic leukaemias and myeloproliferative disorders. Radiother Oncol 2001; 58: 235-246.
191. McFarland JT, Kuzma C, Millard FE et al. Palliative irradiation of the spleen. Am J Clin Oncol 2003; 26: 178-183.
192. World Health Organization. Cancer pain Relief. World Health Organization, Geneva, Swiss, 1986.
193. Ruoff G, Lema M. Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage 2003; 25(suppl. 2): S21-S31.
194. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53: 109-138.
195. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63: 1999-2010.
196. Mercadante S, Radbruch L, Caraceni A et al. Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002; 94: 832-839.
197. Payne R, Coluzzi P, Hart L et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001; 22: 575-583.
198. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002; 20: 348-352.
199. Mercadante S, Casuccio A, Fulfaro F et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19: 2898-2904.
200. Moryl N, Santiago-Palma J et al. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain 2002; 96: 325-328.
201. Portenoy RK. Adjuvant analgesic agents. Hematol Oncol Clin North Am 1996: 10: 103-119.
202. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25: 81-104.
203. Scaramucci L, Bongarzoni V, Niscola P et al. Neuropathy as dominant picture in Primary Amyloidosis: report of a case with severe clinical course. Hematol J 2002; 3(suppl. 1): 418.
204. Johnson RW, Whitton TL. Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin Pharmacother 2004; 5: 551-559.
205. Stalfelt AM. A "good death" needs to be discussed. A study of patients with acute myeloid leukemia demonstrates the value of palliative care (Swedish). Lakartidningen 2003; 100: 4072-4077.
206. Abrahm JL. Waiting for the platelet count to rise: negotiating care at the end of life. Cancer Invest 2003; 21: 772-781.
207. Burucoa B. Discomfort symptoms other than pain at the end of life. Rev Prat 1999; 49: 1051-1056.
208. Chang VT, Ingham J. Symptom control. Cancer Invest 2003; 21: 564-578.
209. Molassiotis A. Anorexia and weight loss in long-term survivors of haematological malignancies. J Clin Nurs 2003; 12: 925-927.
210. Fallon M, O'Neill B. ABC of palliative care. Constipation and diarrhoea. BMJ 1997; 315: 1293-1296.
211. Ripamonti C, Fusco F. Respiratory problems in advanced cancer. Support Care Cancer 2002; 10: 204-216.
212. Mercadante S, Girelli D, Casuccio A. Sleep disorders in advanced cancer patients: prevalence and factors associated. Support Care Cancer 2004; 12: 355-359.
213. dos Santos MJ, Pimentel P, Monteiro JM et al. Psychiatric disorders in hospitalized patients with hematologic neoplasms. Acta Med Port 1991; 4: 5-8.
214. Montgomery C, Pocock M, Titley K, Lloyd K. Predicting psychological distress in patients with leukaemia and lymphoma. J Psychosom Res 2003; 54: 289-292.
215. Campbell ML. Terminal dyspnea and respiratory distress. Crit Care Clin 2004; 20: 403-417.
216. Morrison RS, Meier DE. Clinical practice. Palliative care. N Engl J Med 2004; 350: 2582-2590.
217. Fallon M. Care of the terminally ill cancer patient: a handbook for the medical oncologist. Br J Cancer 2004; 90: 2247.
218. Jackson K, Lipman A. Drug therapy for delirium in terminally ill patients. Cochrane Database Syst Rev 2004; 2: CD004770.
219. Lanuke K, Fainsinger RL, DeMoissac D. Hydration management at the end of life. J Palliat Med 2004; 7: 257-163.
220. Muller-Busch HC, Andres I, Jehser T. Sedation in palliative care - a critical analysis of 7 years experience. BMC Palliat Care 2003; 2: 2.
221. Rousseau PC. Palliative sedation in terminally ill patients. Adv Exp Med Biol 2004; 550: 263-267.
222. Lynch M. Palliative sedation. Clin J Oncol Nurs 2003; 7: 653-657, 667.
223. McGrath P. Dying in the curative system: the haematology/ oncology dilemma. Part I. Aust J Holist Nurs 2001; 8: 22-30.
224. McGrath P. Are we making progress? Not in haematology! Omega (Westport) 2002; 45: 331-348.
225. Auret K, Bulsara C, Joske D. Australasian haematologist referral patterns to palliative care: lack of consensus on when and why. Int Med J 2003; 33: 566-571.
226. McGrath P. End-of-life care for hematological malignancies: the 'technological imperative' and palliative care. Palliat Care 2002; 18: 39-47.
227. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004; 22: 315-321.
228. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002; 162: 1597-1603.
229. Monti M, Cunietti E, Castellani L, Merli M, Cruciatti F. Ten years' activity of the first Italian public hospice for terminally ill patients. Support Care Cancer 2004 (Epub ahead of print), DOI: 10.1007/s00520-004-0617-2
230. Fleishman SB. Treatment of symptom clusters: pain, depression, and fatigue. J Natl Cancer Inst Monogr 2004; 32: 119-123.